The Business Journals6d
Madrigal CEO touts 'amazing' sales success of new MASH drug, but stock slumps
expand Madrigal Pharmaceuticals' NASH pill Rezdiffra is FDA-approved treatment for the fatty liver disease. Madrigal Pharrmaceuticals "I will ask you to look at any [new drug] launch," said Sibold ...
Nasdaq8d
Madrigal Pharmaceuticals Reports Preliminary 2024 Net Sales and Patient Milestones for Rezdiffra™
By the end of 2024, the company anticipates having approximately $931 million in cash and related assets, with over 11,800 patients currently on Rezdiffra, the first FDA-approved treatment for ...
Madrigal Pharmaceuticals’ Rezdiffra Shows Strong Market Growth and Positive Outlook, Justifying Buy Rating
Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target ...